Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006125 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006125 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology.
The verdict
NCT00006125, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have relapsed or refractory intermediate-grade or high-grade non-Hodgkin's lymphoma.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006125
The ClinicalTrials.gov registry entry for NCT00006125 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00006125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006125 about?
NCT00006125 is a clinical study titled "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have rel...
What is the current status of trial NCT00006125?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-07.
What interventions are being tested in trial NCT00006125?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006125?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.